Simplex Trading, LLC Next Cure, Inc. Transaction History

Simplex Trading, LLC

$2.98 Billion
Q2 2024

A detailed history of Simplex Trading, LLC transactions in Next Cure, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 547 shares of NXTC stock, worth $754. This represents 0.0% of its overall portfolio holdings.

Number of Shares

547

Holding current value

$754

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$1.17 - $2.49 $639 - $1,362	547 New	547 $0
Q2 2022 Aug 03, 2022	SELL	$3.38 - $5.27 $682 - $1,064	-202 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$4.76 - $6.24 $633 - $829	-133 Reduced 39.7%	202 $0
Q4 2021 Feb 23, 2022	BUY	$5.7 - $9.1 $1,909 - $3,048	335 New	335 $2,000
Q2 2021 Aug 12, 2021	SELL	$7.6 - $10.28 $12,258 - $16,581	-1,613 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$9.81 - $13.88 $14,204 - $20,098	1,448 Added 877.58%	1,613 $16,000
Q4 2020 Feb 02, 2021	SELL	$9.47 - $12.43 $1,250 - $1,640	-132 Reduced 44.44%	165 $1,000
Q3 2020 Oct 14, 2020	SELL	$8.15 - $21.17 $12,811 - $33,279	-1,572 Reduced 84.11%	297 $2,000
Q2 2020 Jul 13, 2020	BUY	$21.19 - $40.2 $13,879 - $26,331	655 Added 53.95%	1,869 $40,000
Q1 2020 Apr 29, 2020	SELL	$32.32 - $58.37 $517 - $933	-16 Reduced 1.3%	1,214 $45,000
Q4 2019 Feb 05, 2020	BUY	$25.0 - $92.22 $30,750 - $113,430	1,230 New	1,230 $69,000

Others Institutions Holding NXTC

# of Institutions

Shares Held

16M

Call Options Held

1.4K

Put Options Held

Sofinnova Investments, Inc. Menlo Park, CA

2.67M
Shares

$3.69 Million
0.24% of portfolio
Logos Global Management LP San Francisco, CA

2.5M
Shares

$3.45 Million
0.37% of portfolio
Affinity Asset Advisors, LLC New York, NY

1.69M
Shares

$2.33 Million
0.37% of portfolio
Orbimed Advisors LLC San Diego, CA

1.14M
Shares

$1.57 Million
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

987K
Shares

$1.36 Million
0.0% of portfolio

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $38.3M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account